CAPR
CAPRICOR THERAPEUTICS, INC.
Next earnings Aug 10, 2026 · consensus $-0.60 EPS
Last earnings -1.2% on 2026-05-12
$26.44
▼ -13.03%$26.44▲ +244.27%
over 1Y
L $4.60EODHDH $35.34
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-13.0%
1W-9.9%
1M-9.3%
3M-8.5%
YTD-6.6%
1Y+244.3%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 15 analysts
Buy
Conservative balance sheet (liabilities/equity 0.16x); but revenue fell -100.0% YoY.
Revenue (FY2025) $0.00 · FY2025
CAPRICOR THERAPEUTICS, INC. shows $0.00 in FY2025 revenue (-100.0% YoY), and -34.4% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $245K | $2.55M | $25.2M | $22.3M | $0.00 |
| Gross profit | — | — | — | — | — |
| Operating income | -$20.9M | -$29.7M | -$24.1M | -$42.6M | -$108M |
| Net income | -$20.0M | -$29.0M | -$22.3M | -$40.5M | -$105M |
| Diluted EPS | -$0.87 | -$1.18 | -$0.83 | -$1.15 | -$2.26 |
| Net margin | -8175.9% | -1137.4% | -88.5% | -181.7% | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$1.23B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-6.9%
FCF yield-4.8%
Quality & risk
ROIC (est.)-27.9%
Free cash flow-$72.7M
Total debt—
Net cash$288M
Altman Z-Score16.96 safe
Piotroski F-Score2/7
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY+25.9%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-262026-06-26open ↗4Period ending 2026-06-222026-06-24open ↗4Period ending 2026-06-222026-06-24open ↗8-KPeriod ending 2026-06-042026-06-08open ↗4Period ending 2026-05-262026-05-28open ↗3Period ending 2026-05-252026-05-28open ↗4Period ending 2026-05-182026-05-19open ↗144/AFiling2026-05-19open ↗144Filing2026-05-19open ↗4Period ending 2026-05-132026-05-14open ↗10-QPeriod ending 2026-03-312026-05-13open ↗8-KPeriod ending 2026-05-122026-05-12open ↗
Frequently asked
- Is CAPRICOR THERAPEUTICS, INC. (CAPR) a buy?
- CAPR currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.16x); but revenue fell -100.0% YoY.
- What is CAPRICOR THERAPEUTICS, INC.'s quality score?
- CAPR scores 36.179487179487175/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001133869, latest 10-Q filed 2026-05-13) · EODHD · as of 6/26/2026, 6:18:02 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.